Blog

Blog

Corporate Blog & Resources

Client Press Releases

  • Tiziana Life Sciences (NASDAQ: TLSA) Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment

    Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing Initiative Greater Than 1 year Safety Exposure to anti-CD3 Foralumab Has Been Well-Tolerated At-Home Dosing Likely to Improve Patient Compliance to Treatment and Outcomes NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) — Tiziana Life The post Tiziana Life Sciences (NASDAQ: TLSA) Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment appeared first on STOCKIFY MEDIA.

  • Mogul Energy International (OTC: MGUY) Announces Strategic Uplisting Plan for 2024

    MIAMI, Oct. 17, 2023 (GLOBE NEWSWIRE) — Mogul Energy International, a prominent figure in the energy and transportation sector, with a primary focus on transportation, logistics, warehouse consolidation, and distribution services for perishable and time-sensitive cargo, is pleased to announce its strategic intent to uplist to a higher exchange in 2024. The company has officially The post Mogul Energy International (OTC: MGUY) Announces Strategic Uplisting Plan for 2024 appeared first on STOCKIFY MEDIA.

  • Hypercharge (OTCQB: HCNWF) Announces Eevion Integrated Charging with Launch Partners ParkCo and Precise ParkLink

    Vancouver, British Columbia–(Newsfile Corp. – October 10, 2023) – Hypercharge Networks Corp. (NEO: HC) (OTCQB: HCNWF) (FSE: PB7) (the “Company” or “Hypercharge“), a leading, smart electric vehicle (EV) charging solutions provider, is pleased to announce the launch of its integrated charging software solution, Eevion. The new cloud-based platform integrates the Hypercharge EV charging network into any app, platform, The post Hypercharge (OTCQB: HCNWF) Announces Eevion Integrated Charging with Launch Partners ParkCo and Precise ParkLink appeared first on STOCKIFY MEDIA.

  • Okyo Pharma (NASDAQ: OKYO) Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (“DED”)

    Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the entire 12-week trial. The dropout rate is 5.4% and unrelated to side effects. Top-line efficacy and safety data are on schedule The post Okyo Pharma (NASDAQ: OKYO) Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (“DED”) appeared first on STOCKIFY MEDIA.

  • Epazz Holdings’ (OTC: EPAZ) ZenaDrone Predictive Artificial Intelligence Sends the First Manufactured ZenaDrone 1000s for Drone as a Service in Ireland

    CHICAGO, IL, Oct. 03, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Epazz Inc. (OTC: EPAZ), a mission-critical provider of drone technology, artificial intelligence software, cryptocurrency apps, blockchain mobile apps and cloud-based business software solutions, has announced today that ZenaDrone is sending the first drones manufactured from the company’s new manufacturing facility to Ireland. This is the first The post Epazz Holdings’ (OTC: EPAZ) ZenaDrone Predictive Artificial Intelligence Sends the First Manufactured ZenaDrone 1000s for Drone as a Service in Ireland appeared first on STOCKIFY MEDIA.

Subscribe to our newsletter

Sign up to receive latest news, updates, promotions, and special offers delivered directly to your inbox.
No, thanks